UNSPSC 51145301: Aniracetam

This classification denotes a neuroprotective agent with the molecular formula C12H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5L16LKN964, chemically known as 2-pyrrolidinone, 1-(4-methoxybenzoyl)- but more generally known as aniracetam, which bears US NIH Compound Identifier 2196. European Medicines Agency schedules Aniracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05517MIG.

UNSPSC 51145301 Aniracetam (Commodity) shows little relevant recent state and local procurement activity under its nominal scope. The three most recent opportunities posted to state and local procurement boards are misaligned with aniracetam procurement: Seminole County, Florida's IFB solicits naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a contract vehicle for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. None of these solicitations target aniracetam specifically, and the MMCAP RFP, while broad in scope, does not name aniracetam among its focus areas or call for individual pharmaceutical manufacturers to bid on single-drug supply agreements.

The code's actual state and local activity appears concentrated in cooperative purchasing frameworks and health agency pharmacy procurement rather than direct commodity sourcing. Issuing bodies include state health departments (Texas HHS Commission), state procurement offices managing multistate cooperatives (Minnesota Department of Administration), and county public health agencies (Seminole County). The geographic spread spans Florida, Texas, and Minnesota, with multistate coordination through MMCAP extending to Oregon. No recent opportunities specifically target aniracetam procurement, making this code a low-priority watch unless your firm has established relationships with state pharmacy benefit managers or cooperative purchasing administrators seeking niche pharmaceutical suppliers outside traditional wholesale channels.